THERAVANCE INC - CORPORATE OBLIG

CUSIP: 88338TAB0

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class
Debt / CORPORATE OBLIG
Market price (% of par)
99.14%
Total 13F principal
$231,782,480
Principal change
-$1,684,868
Total reported market value
$233,348,280
Number of holders
27
Value change
+$483,783
Number of buys
6
Number of sells
10

Quarterly Holders Quick Answers

What is CUSIP 88338TAB0?
CUSIP 88338TAB0 identifies 88338TAB0 - THERAVANCE INC - CORPORATE OBLIG in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of THERAVANCE INC - CORPORATE OBLIG as of Q2 2020

As of 30 Jun 2020, THERAVANCE INC - CORPORATE OBLIG was held by 27 institutional bondholders reporting positions in Form 13F filings. These institutions reported holding $231,782,480 in principal (par value) of the bond. The largest 10 bondholders included Linden Advisors LP, LAZARD ASSET MANAGEMENT LLC, ADVENT CAPITAL MANAGEMENT /DE/, CNH PARTNERS LLC, Shaolin Capital Management LLC, BNP PARIBAS ARBITRAGE, SA, DeepCurrents Investment Group LLC, Polar Asset Management Partners Inc., Jefferies Group LLC, and BANK OF AMERICA CORP /DE/. This page lists 27 institutional bondholders reporting positions for the Q2 2020 filing period.
Investor Option Weight % Change % Value $ * Price (% of par) Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.